A Phase 1 Study of LY4052031 in People With Urothelial Cancer and Other Solid Tumors

Full Title

A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors

Purpose

Researchers want to find the best dose of LY4052031 to treat people with advanced solid tumors. The people in this study have metastatic solid tumors that came back or keep growing after treatment. In addition, their tumors make a protein called Nectin-4, which plays a role in cancer growth.

LY4052031 targets cells that make Nectin-4. By destroying these cells, LY4052031 may help slow or stop the growth of your cancer. LY4052031 is given intravenously (by vein).

The first part of this study will assess different doses of LY4052031 in people with solid tumors. The best doses of LY4052031 will then be studied in people with urothelial cancers (such as bladder cancer).

Who Can Join

To join this study, there are a few conditions. You must:

• Have urothelial cancer or other solid tumor that is advanced and keeps growing after treatment.
• Have a tumor that makes Nectin-4.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Gopakumar Iyer’s office at 646-888-4737.